Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera Therapeutics to Participate in Upcoming June Investor Conference
07:00am, Thursday, 01'st Jun 2023
WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m
7 Growth Stocks That Could Double Your Money in 2023
02:57pm, Sunday, 14'th May 2023
While the recent slow activity in the major indices clouds the narrative, you can still enjoy opportunities for growth stocks that could double your money. To be sure, you must be willing to accept so
Kymera: More Data Needed
09:14am, Sunday, 14'th May 2023
Kymera produced solid-looking phase 1 data, but Pfizer's problems in the space, along with some safety issues, hurt its stock. When partner Sanofi produces phase 2 data, this company will be considera
Kymera Therapeutics, Inc. (KYMR) Q1 2023 Earnings Call Transcript
06:35pm, Saturday, 06'th May 2023
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Bruce Jacobs - Chief Financial Officer Nello Mainolfi - Founder, President and CEO
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Misses Revenue Estimates
09:55am, Thursday, 04'th May 2023
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.71 per share a year ago.
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
07:00am, Tuesday, 11'th Apr 2023
WATERTOWN, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small
7 Biotech Stocks to Buy for 100% Returns
01:19pm, Sunday, 09'th Apr 2023
Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1.
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
07:00am, Wednesday, 01'st Mar 2023
WATERTOWN, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small
Kymera Therapeutics, Inc. (KYMR) Q4 2022 Earnings Call Transcript
02:43pm, Saturday, 25'th Feb 2023
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Bruce Jacobs - Chief Financial Officer Nello Mainolfi - Founder & Chief Exec
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
09:47am, Thursday, 23'rd Feb 2023
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.26% and 37.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
07:00am, Wednesday, 01'st Feb 2023
Company also presenting at upcoming investor conferences Company also presenting at upcoming investor conferences
Kymera: Data Derisks Platform, But I Will Wait For More
06:58pm, Monday, 23'rd Jan 2023
Kymera Therapeutics, Inc.'s KT-474 HS/AD data de-risked the IRAK4 protein degradation platform, as did Sanofi's partnering. However, more differentiating data seems to be needed in these indications a
All You Need to Know About Kymera Therapeutics, Inc. (KYMR) Rating Upgrade to Buy
01:33pm, Monday, 09'th Jan 2023
Kymera Therapeutics, Inc. (KYMR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
07:00am, Tuesday, 03'rd Jan 2023
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m
7 Perfect Presents to Gift Your 2023 Stock Portfolio
04:57pm, Wednesday, 21'st Dec 2022
New Year 2023 will see a continued tightening of monetary policy as the Federal Reserve attempts to rein in sky-high inflation. Following the 50 basis point rate hike in Dec., there are expectations t
